Selective Serotonin Reuptake Inhibitors (SSRIs) in Pregnancy: An Updated Review on Risks to Mother, Fetus, and Child

Overview

Journal Curr Psychiatry Rep

Publisher Current Science

Specialty Psychiatry

Date 2022 Oct 1

PMID 36181572

Authors

Lindsay G Lebin

Andrew M Novick

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: To provide an updated summary and appraisal of work from 2019 to 2022 examining risks of selective serotonin reuptake inhibitor (SSRI) use in pregnancy.

Recent Findings: Perinatal SSRI exposure does not increase risk of major malformations or gestational diabetes after accounting for underlying maternal illness. SSRIs are associated with small increase in risk of pre-eclampsia, postpartum hemorrhage, preterm delivery, persistent pulmonary hypertension of the newborn, and neonatal intensive care unit admissions, though absolute risk of these outcomes is low. While data suggests no increased risk of neurodevelopmental disorders in offspring, mixed evidence indicates increased risk of adverse cognitive outcomes and affective disorders. Recent evidence suggest low absolute risk of clinically relevant negative outcomes with perinatal SSRI exposure when compared to untreated perinatal depression. However, study design and ability to control for confounding remains an ongoing research challenge, highlighting need for ongoing rigorous study design and analysis.

Citing Articles

Overweight and glucose/lipid metabolism abnormality associated with SSRIs: a pharmacovigilance study based on the FDA adverse event reporting system.

Cao J, Chen Z, Wang Y, Ma Y, Yang Z, Cai J Front Pharmacol. 2025; 15:1517546.

PMID: 39867657 PMC: 11759304. DOI: 10.3389/fphar.2024.1517546.

Premature Constriction of Fetal Ductus Arteriosus Caused by Sertraline in a Pregnant Woman: A Case Report.

Golbabaei A, Alavi Moghaddam E, Mohammad Talebi H Clin Case Rep. 2025; 13(1):e70074.

PMID: 39764265 PMC: 11702413. DOI: 10.1002/ccr3.70074.

Advances in Psychotropic Treatment for Pregnant Women: Efficacy, Adverse Outcomes, and Therapeutic Monitoring.

Costa B, Vale N J Clin Med. 2024; 13(15).

PMID: 39124665 PMC: 11312735. DOI: 10.3390/jcm13154398.

Depression Treatment in Pregnancy: Is It Safe, or Is It Not?.

Gallitelli V, Franco R, Guidi S, Puri L, Parasiliti M, Vidiri A Int J Environ Res Public Health. 2024; 21(4).

PMID: 38673317 PMC: 11049910. DOI: 10.3390/ijerph21040404.

Association between maternal mental health-related hospitalisation in the 5 years prior to or during pregnancy and adverse birth outcomes: a population-based retrospective cohort data linkage study in the Northern Territory of Australia.

Dadi A, He V, Brown K, Hazell-Raine K, Reilly N, Giallo R Lancet Reg Health West Pac. 2024; 46:101063.

PMID: 38659431 PMC: 11040136. DOI: 10.1016/j.lanwpc.2024.101063.

References

Dean K, Stevens H, Mortensen P, Murray R, Walsh E, Pedersen C . Full spectrum of psychiatric outcomes among offspring with parental history of mental disorder. Arch Gen Psychiatry. 2010; 67(8):822-9. DOI: 10.1001/archgenpsychiatry.2010.86. View

Reis M, Kallen B . Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med. 2010; 40(10):1723-33. DOI: 10.1017/S0033291709992194. View

Ornoy A, Koren G . SSRIs and SNRIs (SRI) in Pregnancy: Effects on the Course of Pregnancy and the Offspring: How Far Are We from Having All the Answers?. Int J Mol Sci. 2019; 20(10). PMC: 6567187. DOI: 10.3390/ijms20102370. View

Skalkidou A, Sundstrom-Poromaa I, Wikman A, Hesselman S, Wikstrom A, Elenis E . SSRI use during pregnancy and risk for postpartum haemorrhage: a national register-based cohort study in Sweden. BJOG. 2020; 127(11):1366-1373. DOI: 10.1111/1471-0528.16210. View

Ng Q, Venkatanarayanan N, Ho C, Sim W, Lim D, Yeo W . Selective Serotonin Reuptake Inhibitors and Persistent Pulmonary Hypertension of the Newborn: An Update Meta-Analysis. J Womens Health (Larchmt). 2018; 28(3):331-338. DOI: 10.1089/jwh.2018.7319. View

Andrade S, Reichman M, Mott K, Pitts M, Kieswetter C, Dinatale M . Use of selective serotonin reuptake inhibitors (SSRIs) in women delivering liveborn infants and other women of child-bearing age within the U.S. Food and Drug Administration's Mini-Sentinel program. Arch Womens Ment Health. 2016; 19(6):969-977. DOI: 10.1007/s00737-016-0637-1. View

Moses-Kolko E, Bogen D, Perel J, Bregar A, Uhl K, Levin B . Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005; 293(19):2372-83. DOI: 10.1001/jama.293.19.2372. View

Slomian J, Honvo G, Emonts P, Reginster J, Bruyere O . Consequences of maternal postpartum depression: A systematic review of maternal and infant outcomes. Womens Health (Lond). 2019; 15:1745506519844044. PMC: 6492376. DOI: 10.1177/1745506519844044. View

Curry S, Krist A, Owens D, Barry M, Caughey A, Davidson K . Interventions to Prevent Perinatal Depression: US Preventive Services Task Force Recommendation Statement. JAMA. 2019; 321(6):580-587. DOI: 10.1001/jama.2019.0007. View

10.

Wolgast E, Lilliecreutz C, Sydsjo G, Bladh M, Josefsson A . The impact of major depressive disorder and antidepressant medication before and during pregnancy on obstetric and neonatal outcomes: A nationwide population-based study. Eur J Obstet Gynecol Reprod Biol. 2020; 257:42-50. DOI: 10.1016/j.ejogrb.2020.11.062. View

11.

Rommel A, Bergink V, Liu X, Munk-Olsen T, Molenaar N . Long-Term Effects of Intrauterine Exposure to Antidepressants on Physical, Neurodevelopmental, and Psychiatric Outcomes: A Systematic Review. J Clin Psychiatry. 2020; 81(3). PMC: 8739257. DOI: 10.4088/JCP.19r12965. View

12.

Bar-Oz B, Einarson T, Einarson A, Boskovic R, OBrien L, Malm H . Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors. Clin Ther. 2007; 29(5):918-926. DOI: 10.1016/j.clinthera.2007.05.003. View

13.

Lupattelli A, Spigset O, Koren G, Nordeng H . Risk of vaginal bleeding and postpartum hemorrhage after use of antidepressants in pregnancy: a study from the Norwegian Mother and Child Cohort Study. J Clin Psychopharmacol. 2013; 34(1):143-8. DOI: 10.1097/JCP.0000000000000036. View

14.

Berard A, Iessa N, Chaabane S, Muanda F, Boukhris T, Zhao J . The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: a systematic review and meta-analysis. Br J Clin Pharmacol. 2015; 81(4):589-604. PMC: 4799922. DOI: 10.1111/bcp.12849. View

15.

Huybrechts K, Palmsten K, Avorn J, Cohen L, Holmes L, Franklin J . Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014; 370(25):2397-407. PMC: 4062924. DOI: 10.1056/NEJMoa1312828. View

16.

Bolte A, van Geijn H, Dekker G . Pathophysiology of preeclampsia and the role of serotonin. Eur J Obstet Gynecol Reprod Biol. 2001; 95(1):12-21. DOI: 10.1016/s0301-2115(00)00367-5. View

17.

Heller H, Ravelli A, Bruning A, de Groot C, Scheele F, van Pampus M . Increased postpartum haemorrhage, the possible relation with serotonergic and other psychopharmacological drugs: a matched cohort study. BMC Pregnancy Childbirth. 2017; 17(1):166. PMC: 5457563. DOI: 10.1186/s12884-017-1334-4. View

18.

Fitton C, Steiner M, Aucott L, Pell J, Mackay D, Fleming M . In utero exposure to antidepressant medication and neonatal and child outcomes: a systematic review. Acta Psychiatr Scand. 2019; 141(1):21-33. DOI: 10.1111/acps.13120. View

19.

Wartko P, Weiss N, Enquobahrie D, Chan K, Stephenson-Famy A, Mueller B . Antidepressant continuation in pregnancy and risk of gestational diabetes. Pharmacoepidemiol Drug Saf. 2019; 28(9):1194-1203. PMC: 6728166. DOI: 10.1002/pds.4799. View

20.

Finkel M, Pollock B, Rong J . Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull. 1996; 32(4):653-8. View